Antibody drug development projects require tools for monitoring the concentration of drug candidates in patient samples and standards for measuring anti-drug antibodies. We have used the HuCAL? recombinant antibody technology to generate fully human Fab and IgG anti-idiotypic antibodies binding specifically and with high affinity to a large number of drug candidates as well as to marketed drugs like Herceptin?, Avastin?, Rituxan?, Remicade? , Humira? , and many others. The HuCAL phage display approach allows the selection of inhibitory and non-inhibitory anti-idiotypic antibodies as well as development of antibodies against drug-target complexes. If exceptional sensitivity is required, the affinities of these antibodies can be improved up to hundredfold using molecular evolution, routinely resulting in picomolar binding strengths.
展开▼
